BC-LI-0186

Overview of the chemical compound BC-LI-0186

BC-LI-0186
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

BC-LI-0186 is a chemical compound that has been studied for its potential therapeutic effects, particularly in the context of neurodegenerative disorders. It is a derivative of the amino acid L-DOPA, which is a precursor to the neurotransmitter dopamine.

Chemical Structure

Chemical structure of BC-LI-0186

BC-LI-0186 is characterized by its specific chemical structure, which includes a catechol moiety, similar to that found in dopamine. This structure is crucial for its biological activity, as it allows the compound to interact with various neurotransmitter systems in the brain.

Pharmacological Properties

BC-LI-0186 has been investigated for its ability to cross the blood-brain barrier, a critical factor in its potential use as a therapeutic agent. Once in the brain, it is thought to exert its effects by modulating the levels of dopamine, thereby influencing dopaminergic pathways. This makes it a compound of interest in the treatment of conditions such as Parkinson's disease and other disorders characterized by dopamine deficiency.

Potential Therapeutic Applications

The primary focus of research on BC-LI-0186 has been its application in neurodegenerative diseases. Its ability to enhance dopaminergic activity suggests it could be beneficial in managing symptoms of Parkinson's disease, such as bradykinesia, tremor, and rigidity. Additionally, its neuroprotective properties are being explored for their potential to slow the progression of neurodegeneration.

Mechanism of Action

BC-LI-0186 is believed to function by increasing the availability of dopamine in the brain. It may do this by acting as a dopamine precursor or by inhibiting the breakdown of dopamine, thus prolonging its action at synaptic sites. This mechanism is similar to that of other dopaminergic agents used in clinical practice, but BC-LI-0186 may offer advantages in terms of specificity and reduced side effects.

Research and Development

Research on BC-LI-0186 is ongoing, with studies focusing on its pharmacokinetics, safety profile, and efficacy in animal models of neurodegenerative diseases. Clinical trials are needed to fully establish its therapeutic potential and to determine the optimal dosing regimen for human use.

Related Pages

• L-DOPA
• Dopamine
• Parkinson's disease
• Neurotransmitter
• Neurodegenerative disorder